Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age19+
SponsorSociété Algérienne de Formation et Recherche en Oncologie

About this trial

The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer.

It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged 19 years and older.

Diagnosis of prostate cancer confirmed histologically and/or biologically.

Patients followed in the participating oncology departments.

Written informed consent obtained.

Disqualifiers

None

Trial population

Patients with histologically and/or biologically confirmed prostate cancer, followed in the participating centers.

Trial design

Design model

Other

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Socio-demographic characteristics of patients with prostate cancer in Algeria

Frequency (%) of sociodemographic characteristics of patients with prostate cancer in Algeria, including age at diagnosis, marital status, and socioeconomic level.

Time frame
At Baseline ( Initial visit )
2

Personal and family history of cancer

Frequency (%) of patients with personal and family history of cancer.

Time frame
At Baseline (Initial Visit)
3

Environmental and occupational exposures

Frequency (%) of patients with environmental or occupational exposures.

Time frame
At Baseline (Initial visit)
4

Smoking history

Frequency (%) of patients according to smoking status (current, former, never).

Time frame
At Baseline (Initial visit)

Secondary outcomes

1

Diagnosis by PSA testing

% of patients diagnosed by PSA testing.

Time frame
At Baseline (Initial visit)
2

Diagnosis by imaging

% of patients diagnosed by imaging.

Time frame
At Baseline (Initial visit)
3

Diagnosis by biopsy

% of patients diagnosed by biopsy.

Time frame
At Baseline (Initial visit)
4

Time from symptom onset to first medical consultation

Median time (in days) between onset of first symptoms and first medical consultation.

Time frame
At Baseline (Initial visit)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Société Algérienne de Formation et Recherche en Oncologie

Lead sponsor

ES Clinical Research

Collaborator

Ipsen

Collaborator

Astellas Pharma Inc

Collaborator